These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31240525)

  • 1. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
    Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
    J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
    Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
    Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
    Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
    Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
    Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
    J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chordoma: Immunohistochemical Analysis of Brachury.
    Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
    Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
    Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
    Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T gene isoform expression pattern is significantly different between chordomas and notochords.
    Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
    Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
    Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
    J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors.
    Tamura R; Sato M; Morimoto Y; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Murase M; Yoshida K; Toda M
    Exp Mol Pathol; 2020 Jun; 114():104408. PubMed ID: 32088190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.
    Jambhekar NA; Rekhi B; Thorat K; Dikshit R; Agrawal M; Puri A
    Arch Pathol Lab Med; 2010 Aug; 134(8):1181-7. PubMed ID: 20670140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma.
    Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP
    J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Prospects for Molecular Targets for Chordomas.
    Ozair MZ; Shah PP; Mathios D; Lim M; Moss NS
    Neurosurg Clin N Am; 2020 Apr; 31(2):289-300. PubMed ID: 32147018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.
    Talagas M; Uguen A; Garlantezec R; Fournier G; Doucet L; Gobin E; Marcorelles P; Volant A; DE Braekeleer M
    Anticancer Res; 2013 May; 33(5):2065-75. PubMed ID: 23645757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
    Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
    J Neurosurg; 2020 Jan; 132(1):140-149. PubMed ID: 30641849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
    Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
    Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
    Luo P; Wang X; Zhou J; Li L; Jing Z
    Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
    Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
    World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chordoma].
    George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
    Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
    Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
    Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.